NGM Biopharmaceuticals, Inc.
NGM · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $70,864 | $401,349 | $1,365,183 | $2,074,804 |
| - Cash | $58,815 | $73,456 | $151,795 | $147,017 |
| + Debt | $0 | $5,385 | $10,462 | $0 |
| Enterprise Value | $12,049 | $333,278 | $1,223,850 | $1,927,787 |
| Revenue | $4,417 | $55,333 | $77,882 | $87,368 |
| % Growth | -92% | -29% | -10.9% | – |
| Gross Profit | $2,196 | $49,349 | $69,983 | -$76,604 |
| % Margin | 49.7% | 89.2% | 89.9% | -87.7% |
| EBITDA | -$144,326 | -$154,918 | -$120,695 | -$103,833 |
| % Margin | -3,267.5% | -280% | -155% | -118.8% |
| Net Income | -$142,375 | -$159,085 | -$113,826 | -$93,993 |
| % Margin | -3,223.3% | -287.5% | -146.2% | -107.6% |
| EPS Diluted | -1.73 | -1.99 | -1.48 | -1.37 |
| % Growth | 13.1% | -34.5% | -8% | – |
| Operating Cash Flow | -$132,202 | -$144,439 | -$73,229 | -$83,496 |
| Capital Expenditures | -$1,252 | -$1,858 | -$1,684 | -$1,879 |
| Free Cash Flow | -$133,454 | -$146,297 | -$74,913 | -$85,375 |